Huntington National Bank Has $646,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Huntington National Bank reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,986 shares of the medical equipment provider’s stock after selling 144 shares during the quarter. Huntington National Bank’s holdings in Zimmer Biomet were worth $646,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ashton Thomas Securities LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth about $28,000. Crewe Advisors LLC bought a new stake in Zimmer Biomet during the 1st quarter valued at $31,000. Bangor Savings Bank bought a new stake in shares of Zimmer Biomet during the 3rd quarter valued at $31,000. Family Firm Inc. purchased a new stake in shares of Zimmer Biomet in the second quarter worth about $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Zimmer Biomet in the 2nd quarter valued at $43,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ZBH. Robert W. Baird reduced their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. BTIG Research decreased their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Raymond James cut their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Truist Financial upped their target price on shares of Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a research report on Friday, November 1st. Finally, Canaccord Genuity Group lowered their price target on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, September 10th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $123.22.

Zimmer Biomet Stock Up 3.4 %

NYSE ZBH opened at $112.54 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a market cap of $22.40 billion, a PE ratio of 21.40, a P/E/G ratio of 2.00 and a beta of 1.02. The stock’s 50 day moving average is $106.28 and its 200 day moving average is $110.11.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.65 earnings per share. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.